(function(){var loadHandler=window['sl_{C24887DA-9C75-403B-8BC9-B0BB35DA68CE}'];loadHandler&&loadHandler(12, '<div id="spr0_227922"><div id="spr1_227922" class="kern"><img id="img2_227922" src="data/img6.png" width="960px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_227922" class="kern"><div id="spr3_227922" style="left:20.098px;top:156.602px;"><img id="img0_227922" src="data/img37.png" width="920" height="214" alt="" style="left:-0.098px;top:0.193px;"/></div><div id="spr4_227922" style="left:83.106px;top:412.11px;"><div style="width:0px;"><span id="txt0_227922" class="relpos" style="left:7.2px;top:1.684px;">It is usually difficult to distinguish maligancy and low-grade dysplasia by the pattern of</span></div><div style="width:0px;"><span id="txt1_227922" class="relpos" style="left:7.2px;top:23.284px;">enhancement.</span></div></div><div id="spr5_227922" style="left:752.58px;top:501.844px;"><div style="width:0px;"><span id="txt2_227922" class="relpos" style="left:7.2px;top:4.31px;">Fujita, </span><span id="txt3_227922" class="relpos" style="left:7.195px;top:4.31px;">et al  EUS 2016</span></div></div><div id="spr6_227922" style="left:122.795px;top:23.731px;"><div style="width:0px;"><span id="txt4_227922" class="relpos" style="left:7.2px;top:-5.441px;">Can CE-EUS predict malignancy  risk in IPMN</span><span id="txt5_227922" class="relpos" style="left:7.195px;top:-1.348px;">?</span></div></div><div id="spr7_227922" style="left:-1px;top:68px;"><img id="img1_227922" src="data/img36.png" width="966" height="11" alt=""/></div></div></div>');})();